Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News
August 18th 2025

On the Path to Greater Precision in Treating Multiple Myeloma

August 13th 2025

Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk

August 12th 2025

How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community

August 5th 2025

PET/CT Helps Predict Relapse in Patients With Myeloma Undergoing CAR T-Cell Therapy

July 28th 2025

Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Video Interviews
View All
August 18th 2025

Outpatient Models Boost Cost-Effectiveness of CAR T and Bispecific Therapy in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP

August 15th 2025

Leveraging MRD Testing to Advance Value-Based Care in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP

August 14th 2025

Balancing Cost, Coverage, and Clinical Value in First-Line Multiple Myeloma Care: Emilie Aschenbrenner, PharmD, BCOP

August 13th 2025

CEPHEUS Trial Data Reinforce DVRd as New Standard for Multiple Myeloma: Saad Z. Usmani, MD, MBA

August 12th 2025

Emerging Multiple Myeloma Data and Future Outlook From ASCO 2025

August 11th 2025

Integrating CAR T-Cell Therapy and Bispecific Antibodies Into Hematologic Malignancy Care: Anita D’Souza, MD

August 7th 2025

Safety Should Always Be a Priority With CAR T for Multiple Myeloma: Surbhi Sidana, MD, MBBS

August 5th 2025

Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials

August 5th 2025

PERSEUS and ADVANCE Updates: Evolving Approaches to MRD-Driven Myeloma Care

July 30th 2025

Linvoseltamab Approval Expands Access, Increases Competition in BCMA Bispecifics Space: Sundar Jagannath, MBBS

Continuing Medical Education
View All
August 19th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 19th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
August 19th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
August 19th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 19th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Dr Sundar Jagannath
July 29th 2025

Linvoseltamab May Bring Multiple Myeloma Care Closer to Home: Sundar Jagannath, MBBS

Brooke McCormick Sundar Jagannath, MBBS
The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community settings, according to Sundar Jagannath, MBBS.
4 experts in this video
July 29th 2025

Key Takeaways From CEPHEUS: Subgroup Analysis

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that even higher-risk and less-fit patients can benefit from 4-drug combinations while maintaining acceptable safety profiles.
4 experts in this video
July 29th 2025

Expert Perspectives on Balancing QOL, Convenience, and Depth of Treatment Response

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how quality of life (QOL) and treatment convenience should be balanced with maximal depth of response through personalized therapy approaches, emphasizing the importance of multidisciplinary care teams and the flexibility to adapt treatment regimens based on individual patient preferences and circumstances.
4 experts in this video
July 22nd 2025

Therapy Selection and Management Strategies for Transplant-Ineligible Older Patients

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how newer immune-based therapies and bispecific antibodies may enable fixed-duration treatment approaches that could eliminate the need for stem cell transplant in older but fit patients, potentially allowing for treatment-free intervals after achieving deep responses.
4 experts in this video
July 22nd 2025

Balancing Deeper Response and MRD Negativity With Toxicity Risks in Clinical Decision-Making

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how to balance achieving deeper MRD-negative responses against increased toxicity risks in transplant-ineligible patients by personalizing therapy through dose modifications, weekly vs twice-weekly dosing schedules, and careful monitoring while maintaining treatment intensity similar to clinical trials.
Dr Hans Lee
July 18th 2025

Practical Considerations, Future Outlook for Linvoseltamab in Multiple Myeloma Care: Hans Lee, MD

Brooke McCormick Hans Lee, MD
In part 2, Hans Lee, MD, shares practical tips for using linvoseltamab in heavily pretreated multiple myeloma and outlines trials that may expand its future role.
4 experts in this video
July 15th 2025

Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for personalized treatment strategies that consider individual patient frailty and high-risk genetics rather than applying uniform approaches across all older patients.
4 experts in this video
July 15th 2025

Evolving Treatment Strategies in Transplant-Ineligible NDMM: Expert Insights From CEPHEUS, IMROZ and BENEFIT

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how the CEPHEUS trial demonstrated that quadruplet therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone) significantly improved minimal residual disease negativity rates compared to triplet therapy in transplant-ineligible multiple myeloma patients, achieving approximately 60% vs 47% 10–5 responses while maintaining manageable safety profiles.
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic
July 8th 2025

Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD

Cameron Santoro
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
4 experts in this video
July 8th 2025

Advancing Frontline Therapy in Transplant-Eligible Myeloma and Emerging Trends in Smoldering Myeloma Management

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while considering the cost implications and need for sustainable care models.
4 experts in this video
July 8th 2025

Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic
July 7th 2025

Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD

Cameron Santoro
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Multiple myeloma words appearing on table | Image credit: ibreakstock - stock.adobe.com
July 1st 2025

Lower Tregs Linked With Survival in Multiple Myeloma

Jared Kaltwasser
The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick
The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Mansi Shah, MD
June 30th 2025

Why a Patient With Multiple Myeloma Might Decline Stem Cell Transplant: Mansi Shah, MD

Hayden E. Klein Laura Joszt, MA Mansi Shah, MD
Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.
These studies highlight that multiple myeloma outcomes are not solely determined by disease biology or available therapies. | Image Credit: wladimir1804 - stock.adobe.com
June 28th 2025

Highlighting Disparities in Myeloma Outcomes, the Impacts of Comorbidities

Kimberly Rath, PharmD
Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 American Society of Clinical Oncology annual meeting.
Mansi Shah, MD
June 27th 2025

How Transplant, CAR T, and Bispecifics Fit Into Myeloma Care: Mansi Shah, MD

Hayden E. Klein Laura Joszt, MA Mansi Shah, MD
Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.
4 experts in this video
June 27th 2025

Balancing Timing of ASCT: Insights on Delayed Transplantation and Long-Term Treatment Outcomes

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how autologous stem cell transplant (ASCT) deferral should be approached cautiously with concrete medical reasons, as transplant continues to provide superior progression-free survival and potentially curative outcomes for a subset of patients.
4 experts in this video
June 27th 2025

Tailoring Maintenance Therapy by Patient Risk: Lenalidomide Alone vs Combination Approaches

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how maintenance therapy should be tailored based on risk profiles, with standard-risk patients receiving single-agent lenalidomide while high-risk patients may benefit from combination maintenance strategies to achieve more durable responses.
Dr Xavier Leleu
June 25th 2025

Self-Administered Subcutaneous Isatuximab May Ease Multiple Myeloma Treatment Burden: Xavier Leleu, MD, PhD

Brooke McCormick Xavier Leleu, MD, PhD
On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for relapsed/refractory multiple myeloma.
Dr Xavier Leleu
June 25th 2025

Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD

Brooke McCormick Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.
Francesco Sparano, MSc
June 25th 2025

Quality of Life Disparities Persist in R/R Multiple Myeloma Despite Universal Health Care: Francesco Sparano, MSc

Brooke McCormick Francesco Sparano, MSc
Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the Italian-based GIMEMA Foundation.
Dr Sundar Jagannath
June 25th 2025

Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS

Brooke McCormick Sundar Jagannath, MBBS
Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai.
4 experts in this video
June 20th 2025

The Role of MRD Status in Post-ASCT Treatment Decisions and Clinical Integration

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how minimal residual disease (MRD) status can guide post-transplant treatment decisions, particularly for high-risk patients who don’t achieve MRD negativity and patients considering discontinuation of long-term maintenance therapy.
4 experts in this video
June 20th 2025

Evaluating First-Line Treatment Options: Quadruplet vs Triplet Regimens and NCCN Guidelines

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN guidelines now recommending 4-drug regimens for transplant-eligible patients.
Westin Forrestal Princeton | Image: Westin
June 19th 2025

Value-Based Care Calls for Putting Novel Therapies Closer to Patients

Mary Caffrey
Coverage from IVBM Princeton, held May 8, 2025.
Surbhi Sidana, MD, MBBS, Stanford University
June 19th 2025

CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS

Maggie L. Shaw Surbhi Sidana, MD, MBBS
Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
June 18th 2025

DVRd vs VRd in Transplant-Ineligible Myeloma: Insights From Saad Z. Usmani, MD, MBA

Maggie L. Shaw Saad Z. Usmani, MD, MBA, FACP, FASCO
CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status may affect therapeutic decision-making.
4 experts in this video
June 13th 2025

Treatment Approaches and Goals: Transplant-Eligible vs. Transplant-Ineligible Patients

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how treatment strategies differ between transplant-eligible and transplant-ineligible multiple myeloma patients, with transplant eligibility determined by functional status rather than age alone, and how quadruple therapy regimens are increasingly used for transplant-eligible patients to achieve deep, durable responses.
4 experts in this video
June 13th 2025

The Role of ASCT in Frontline Myeloma: Comparative Risks and Benefits with Other Standard Treatment Approaches

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how autologous stem cell transplant remains essential in frontline multiple myeloma management despite improved quadruple therapy outcomes, emphasizing that current evidence still supports transplantation for eligible patients rather than deferring it.
12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo